Adenosine triphosphate/pH dual-responsive controlled drug release system with high cancer/normal cell selectivity and low side toxicity. (August 2022)

• Record Type: Journal Article
• Authors: Fu, Bo; Lin, Hui-Chao; Chen, Nian; Zhao, Ping
• Is Part Of: Journal of biomaterials applications. Volume 37:Number 2(2022)
• Page Start: 324
• Page End: 332
• Publication Date: 2022-08
• Subjects: drug-delivery systems -- adenosine triphosphate/pH responsive -- cancer/normal selectivity -- biosafety -- tumor suppression; Biomedical engineering -- Periodicals; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1177/08853282221087412
• Languages: English
• ISSNs: 0885-3282

Abstract

Most drug-delivery systems (DDS) suffer from poor selectivity to cancer/normal cells or the complicated synthetic process. Herein, we employed a novel facile method to develop an oligodeoxy nucleotides based DDS composed with adenosine-5 ′ - triphosphate (ATP) aptamer and a pH responsive cytosine (C) DNA fragment for specific daunomycine (DNM) delivery. The DDS has ATP/pH dual-responsive drug release, can selectively internalize into tumor cell lines and thus has ultrahigh cancer/normal cell selectivity over the individual drug. The non-chemical synthesis, controllable dual-responsive intracellular drug release, and high cancer/normal cell selectivity endowed the DDS high biocompatibility and significant tumor suppression.